Fogler W E
Biologics Evaluation Section, National Cancer Institute, Bethesda, Maryland 20892.
Biotechnol Ther. 1989;1(1):69-83.
The clinical potential and the limitations of synthetic muramyl peptides have been suggested through extensive work describing their immunomodulating properties and toxicology. The intent of this paper is to offer the clinician a summary of these studies and to introduce the reader to the biological effects associated with administration of muramyl peptides.